The head of the U.S. National Institutes of Health, Francis Collins, said he believes COVID-19 vaccine booster doses will be expanded despite a panel of Food and Drug Administration (FDA) experts recommending against them for the general population. With an overwhelming majority, the panel voted against recommending Pfizer’s COVID-19 booster for most of the general population but later approved them for individuals aged 65 and older, who are the most likely to suffer severe symptoms from the disease. Some scientists on the panel expressed concerns that side-effects associated with the vaccine such as myocarditis, a type of heart inflammation, are not properly understood and suggested that young people don’t need boosters for now. But in an interview on Sunday morning, Collins, whose agency does not oversee the FDA, said that the booster doses will be approved in the future. “I think the big news is that they actually did approve …